Eupraxia Pharmaceuticals (EPRX) announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Key New Findings from the RESOLVE Trial: Tissue Health Outcomes: At 12 weeks after administration, patients who received the highest dose level of EP-104GI, demonstrated the greatest improvement from baseline measured to date, representing near-complete normalization of tissue health; At 36 weeks after administration, patients in the 4mg/site dose groups maintained the tissue health improvements seen at week 12; A dose-response relationship in EoEHSS Grade and Stage was observed across the EP-104GI dose cohorts ranging from 2.5mg/site to 8 mg site
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Promising Prospects for Eupraxia Pharmaceuticals’ EP-104GI in Eosinophilic Esophagitis Treatment
- Eupraxia Pharmaceuticals Reports Promising 52-Week Data for EoE Treatment
- Eupraxia Pharmaceuticals’ EP-104GI shows efficacy in follow-up esophagitis data
- Eupraxia Pharmaceuticals: Buy Rating Backed by Strong Pipeline Advancements and Robust Financial Position